【文章名】Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid Arthritis: Discovery of (E)-1-(4((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)
Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid Arthritis: Discovery of (E)-1-(4((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)
作者
BAGDANOFF JEFFREY T; DONOVIEL MICHAEL S; NOURALDEEN AMR; CARLSEN MARIANNE; JESSOP THEODORE C; TARVER JAMES; ALEEM SAADAT; DONG LI; ZHANG HAIMING; BOTEJU LAKMAL; HAZELWOOD JILL; YAN JACK; BEDNARZ MARK; LAYEK SUMAN; OWUSU IRIS B; GOPINATHAN SUMA; MORAN LIAM; LAI ZHONG; KRAMER JEFF; KIMBALL S DAVID; YALAMANCHILI PADMAJA; HEYDORN WILLIAM E; FRAZIER KENNY S; BROOKS BARBARA; BROWN PHILIP; WILSON ALAN; SONNENBURG WILLIAM K; MAIN ALAN; CARSON KENNETH G; ORAVECZ TAMAS; AUGERI DAVID J
[摘要]：Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4-tetrahydroxy-butyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.
